Litcius/Paper detail

Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study

Alan K. Percy, Jeffrey L. Neul, Tim A. Benke, Elizabeth Berry‐Kravis, Daniel G. Glaze, Eric D. Marsh, Amy Barrett, Di An, Kathie M. Bishop, James M. Youakim

2024Med21 citationsDOIOpen Access PDF

Topics & Concepts

lilacTerm (time)Rett syndromeOpen labelMedicinePharmacologyAdverse effectChemistryBiologyHorticulturePhysicsBiochemistryQuantum mechanicsGeneGenetics and Neurodevelopmental DisordersChild Nutrition and Feeding IssuesFamily and Disability Support Research
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study | Litcius